University of Cape Town / Newsroom & publications / Daily newsPosted: December 10, 2012
Dr Tim Wells, MMV’s Chief Scientific Officer, said: “This is a great achievement and an excellent example of the quality of research that can be fostered in Africa. We look forward to seeing more exciting compounds emerge from Kelly’s team and are proud to be collaborating with H3-D; not only is it conducting excellent science today, but it is also providing world-class training for the next generation of African scientists.”
What is so unique and exciting about MMV390048
It is very potent: it displayed a complete cure of animals infected with malaria parasites in a single dose given orally, and thus has the potential to cure millions of people.
It is active against a wide panel of resistant strains of the malaria parasite.
Developing the drug has made possible the training of more than 10 local scientists and cemented a strong relationship with an international partner.
The clinical candidate is in line to enter clinical trials in late 2013.
View a video of Prof Kelly Chibale speaking about H3-D.